Non-Hodgkin Lymphoma (NHL) Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Increasing Investments by Market Players
   3. Market Restraints
      1. High Treatment Costs
      2. Limited Access to Novel Therapies
   4. Market Opportunity
      1. Rising Demand for Oral Drugs
   5. Market Trends
      1. Adoption of Combination Therapies
5. MARKET SEGMENTATION
   1. By Type
      1. B-Cell Lymphomas
      2. T-Cell Lymphoma
   2. By Treatment Type
      1. Chemotherapy
      2. Targeted Therapy
      3. Others
   3. By Route of Administration
      1. Oral
      2. Parenteral
      3. Others
   4. By End-Users
      1. Hospitals
      2. Homecare
      3. Speciality Centres
      4. Others
   5. By Distribution Channel
      1. Hospital Pharmacy
      2. Online Pharmacy
      3. Retail Pharmacy
   6. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. AbbVie Inc. (Ireland)
      2. Abbott (U.S.)
      3. AbbVie Inc. (U.S.)
      4. Aurobindo Pharma (India)
      5. Amneal Pharmaceuticals LLC. (U.S.)
      6. AstraZeneca (U.K.)
      7. Bausch Health Companies Inc. (Canada)
      8. Bayer AG (Germany)
      9. Cipla Inc. (U.S.)
      10. Eli Lilly and Company (U.S.)
      11. GlaxoSmithKline plc (U.K.)
      12. Hikma Pharmaceuticals PLC (U.K.)
      13. Johnson & Johnson Private Limited (U.S.)
      14. Lupin (India)
      15. LEO Pharma A/S (Denmark)
      16. Merck & Co., Inc. (U.S.)
      17. Merck KGaA (Germany)
      18. Mylan N.V. (U.S.)
      19. Novartis AG (Switzerland)
      20. Pfizer Inc. (U.S.)
      21. Sanofi (France)
      22. Sun Pharmaceutical Industries Ltd. (India)
      23. Teva Pharmaceutical Industries Ltd.(Israel)

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Non-Hodgkin Lymphoma (NHL) market?

The global market of Non-Hodgkin Lymphoma (NHL) is projected to reach USD 22.18 Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Non-Hodgkin Lymphoma (NHL) market?

The global Non-Hodgkin Lymphoma (NHL) market has an estimated annual growth rate of 8.50%.

Q.3. What are the recent trends of Non-Hodgkin Lymphoma (NHL) market?

Adoption of combination therapiesisone of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Non-Hodgkin Lymphoma (NHL)?

The major companies profiled in this report include AbbVie Inc. (Ireland), Abbott (U.S.), AbbVie Inc. (U.S.), Aurobindo Pharma (India), Amneal Pharmaceuticals LLC. (U.S.), AstraZeneca (U.K.), Bausch Health Companies Inc. (Canada), Bayer AG (Germany), Cipla Inc. (U.S.), Eli Lilly and Company (U.S.), GlaxoSmithKline plc (U.K.), Hikma Pharmaceuticals PLC (U.K.), Johnson & Johnson Private Limited (U.S.), Lupin (India), LEO Pharma A/S (Denmark), Merck & Co., Inc. (U.S.), Merck KGaA (Germany), Mylan N.V. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Sanofi (France), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd.(Israel), among others.

Q.5. Which is the largest regional market in the Non-Hodgkin Lymphoma (NHL)?

North America is the largest regional market for Non-Hodgkin Lymphoma (NHL).